On like-to-like financials, the CDMO business that contributes 57% of revenues, declined 8% YoY to Rs 2164 crore. The complex hospital generics business grew 28% due to strong demand for the inhalation anesthesia portfolio. The consumer health business sales rose 5% to Rs 206 crores driven by sustained marketing and brand building efforts
